Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This report highlights that oral Janus kinase inhibitors, including baricitinib, ritlecitinib, deuruxolitinib, and brepocitinib, show promise for treating alopecia areata by promoting substantial hair regrowth with mild-to-moderate side effects, positioning them as a favorable alternative to corticosteroids.

This review concluded that JAK inhibitors are effective in achieving meaningful hair regrowth in moderate to severe alopecia areata, although continuous therapy is often needed to maintain the benefits.

In this study, authors present a case where a 26-year-old patient with alopecia areata experienced relapse after initially responding to Tofacitinib, mitigated by corticosteroids, highlighting challenges and potential insights into the treatment and pathogenesis of the condition.

This review suggests that novel treatment developments targeting the pathomechanics of alopecia areata, such as JAK inhibitors, show promise, although optimal treatment strategies are still under investigation.

This review discusses recent findings on the efficacy of JAK inhibitors for treating alopecia areata, highlighting their role in reversing hair loss by targeting the JAK-STAT signaling pathway, though questions about their effectiveness and safety remain.

In this case report, a 24-year-old woman with Down syndrome effectively managed coexisting alopecia areata and hidradenitis suppurativa using upadacitinib, following partial success with previous treatments.

This study found that black phosphorus nanosheets positively influence skin repair by enhancing angiogenesis, anti-inflammatory response, collagen deposition, and re-epithelialization in a rat model of skin wounds, potentially through activating the JAK-STAT-OAS signaling pathway.

This study found that TLR3-mediated damage sensing can stimulate prostaglandin and Wnt pathways, potentially coordinating hair follicle regeneration in mice with large skin wounds.

This study reported that inhibiting the JAK-STAT pathway with baricitinib restored cellular homeostasis, delayed senescence, and reduced proinflammatory markers in Hutchinson-Gilford progeria syndrome cell models.

In this case report, a 23-year-old man with Crohn's disease experienced near-complete resolution of alopecia universalis after 7 months of upadacitinib treatment, suggesting potential benefits for treating concurrent alopecia areata and Crohn's disease.

Lasheras-Pérez et al. reported that JAK3 and TYK2 proteins are activated in certain forms of primary cicatricial alopecia, suggesting the JAK/TYK/STAT pathway as a potential therapeutic target for these conditions.

This review discusses the role of the JAK/STAT pathway in managing alopecia areata and emphasizes the need for further research to determine the ideal JAK inhibitor, as it reports no new clinical results.

In this study, researchers found that alopecia areata patients show a significant reduction in suppressive regulatory T-cells and an increase in inflammatory T-cell populations, suggesting an immunological imbalance contributing to the disease.

This study suggests that frontal fibrosing alopecia is a highly inflammatory disease involving TH1 and JAK-STAT pathways, without reduced hair keratins, highlighting JAK-STAT signaling as a potential therapeutic target.

This study found that miRNA-24 downregulates the KLF6 gene, influencing coat color by affecting melanogenesis pathways in Cashmere goats, and that miRNA-24 inhibition increased melanin content in mice.

This study reports that Broussonetia papyrifera extract significantly increased hair count over 12 weeks in a small clinical trial and promoted dermal papilla cell proliferation in vitro by regulating WNT-β-catenin and STAT6 pathways.

This research found that kaempferol, a flavonoid from hair growth-promoting plants, significantly enhanced human dermal papilla cell proliferation and inhibited specific signaling pathways, outperforming minoxidil, with topical application in mice promoting hair growth and thickness, indicating potential as a natural hair loss treatment.

This study found that epidermal growth factor significantly enhances the proliferation of hair follicle-derived mesenchymal stem cells through the EGFR/ERK and AKT pathways, without involving the STAT3 pathway.

This study found that inhibiting JAK signaling can unexpectedly trigger hair growth in resting-phase mouse skin, implicating JAK-STAT pathways and oncostatin M in maintaining hair follicle stem cell quiescence.

The study reports that Fgf18 and Tgf-β2 signaling pathways in hair follicle stem cells have opposing effects on the timing of hair cycle transitions, influencing the shift from telogen to anagen phases.

This presentation argues that post-exposure syndromes like PSSD and Long COVID form a coherent group of conditions driven by complex interactions in high-dimensional state spaces rather than singular molecular pathways.

This narrative review highlights the potential of naturally occurring compounds to target specific molecular pathways and overcome resistance in advanced and recurrent papillary thyroid cancer, offering new therapeutic possibilities beyond traditional treatments like surgery and lifelong hormone replacement.

Targeting immune pathways like JAK/STAT may help treat frontal fibrosing alopecia.

This study observed that Epigallocatechin-3-gallate (EGCG) can inhibit phosphorylation of STAT1 and reduce a specific subset of immune cells in vitro and ex vivo, suggesting a potential role in maintaining immune privilege in alopecia areata.

This study found that 3-Deoxysappanchalcone may stimulate hair growth in mice by promoting proliferation of hair follicle dermal papilla cells through WNT/β-catenin and STAT signaling modulation.

This study suggests that mesenchymal stem cell therapy may improve cell viability and regulate key signaling pathways in vitro for treating alopecia areata.

In this study, exosomes from hypoxia-conditioned mesenchymal stem cells significantly improved SOCS3 and STAT3 expression in a mouse model of androgenetic alopecia, suggesting they may offer a more effective therapeutic approach than minoxidil by restoring follicular homeostasis.

This review explores emerging therapies for hair regrowth, highlighting two strategies: hair follicle neogenesis and Wnt/B-catenin pathway modulation, which show promise for treating alopecia by potentially offering more effective options than existing treatments.

This study found that hair follicle stem cells in the hairpoor mouse, a model for Marie-Unna hypotrichosis, lose their quiescent state, leading to a disordered hair cycle and contributing to alopecia.

This study found that dysregulated microRNA expression in mice may be linked to aberrant gene activity that contributes to the development of alopecia areata.